anti-CD3 anti-CMV bispecific antibody-armed activated T-cells (Wayne State University/Transtarget)

N/A

Report date: 2026/03/19 16:57:17

Base Information

Drug Nameanti-CD3 anti-CMV bispecific antibody-armed activated T-cells (Wayne State University/Transtarget)
Drug Alias Nameanti-CD3 CMVBi-armed ATCs (Wayne State University/Transtarget)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 inhibitors
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsCytomegalovirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTranstarget
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTranstargetWayne State University
Active IndicationsN/A
Inactive IndicationsCytomegalovirus Infections

Other Information

ATC CodeN/A
Related LinksN/A